Earnings Call Summary | Novanta(NOVT.US) Q1 2024 Earnings Conference
Earnings Call Summary | Novanta(NOVT.US) Q1 2024 Earnings Conference
The following is a summary of the Novanta Inc. (NOVT) Q1 2024 Earnings Call Transcript:
以下是諾萬塔公司(NOVT)2024年第一季度業績電話會議記錄的摘要:
Financial Performance:
財務業績:
Novanta Inc. reported Q1 2024 revenue at $231 million, a 5% year-on-year growth and a 4% decline on an organic basis.
The company's adjusted gross margins were at 46%, showing a slight increase compared to the previous year.
Adjusted EBITDA stood at $50 million, exceeding prior expectations.
A significant surge in operating cash flow was seen, growing to approximately $33 million, over 200% growth year-over-year.
Novanta Inc.報告稱,2024年第一季度收入爲2.31億美元,同比增長5%,有機下降4%。
該公司調整後的毛利率爲46%,與去年相比略有增長。
調整後的息稅折舊攤銷前利潤爲5000萬美元,超出先前的預期。
運營現金流大幅增長,增至約3,300萬美元,同比增長超過200%。
Business Progress:
業務進展:
Novanta experienced strong growth in medical technology markets, while the life sciences and advanced industrial markets were weaker due to economic hurdles.
The company is on pace to launch a record number of new products in 2024, largely focusing on intelligent subsystems in growth applications.
Novanta plans on pursuing additional acquisitions.
Positive progress is being made with the integration of the recently acquired Motion Solutions.
Q1 operational expenditures were reported at $67 million, predicted to rise to approximately $69 million in Q2 due to increased R&D investments.
A majority of new product launches are on track, promising to generate incremental revenue of $50 million or more by 2025.
Novanta在醫療技術市場經歷了強勁的增長,而由於經濟障礙,生命科學和先進工業市場表現疲軟。
該公司有望在2024年推出創紀錄數量的新產品,主要側重於增長應用中的智能子系統。
Novanta計劃進行更多收購。
最近收購的運動解決方案的整合正在取得積極進展。
第一季度的運營支出爲6,700萬美元,由於研發投資的增加,預計第二季度將增至約6,900萬美元。
大多數新產品的發佈已步入正軌,有望到2025年產生5000萬美元或以上的增量收入。
More details: Novanta IR
更多詳情: Novanta IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。
譯文內容由第三人軟體翻譯。